AKT1 and prostate carcinoma: Chen and colleagues probed the PI3K/AKT pathway using the tumor suppressor inositol polyphosphate 4-phosphatase B (INPP4B) on prostate cancer cells, finding that overexpression of INPP4B led to increased sensitivity to docetaxel [252].